Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.
- NeuroStrip gains UK MHRA regulatory clearance
- Commercial supply enabled across England, Scotland, and Wales
- Early pilot programs underway with top UK universities and British Olympics
- UK registration complements existing US FDA approval
- Supports Control Bionics’ broader European expansion strategy
UK MHRA Registration Unlocks Market Access
Control Bionics Limited (ASX:CBL) has crossed a pivotal regulatory milestone by securing registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its NeuroStrip wearable surface electromyography (sEMG) device. This clearance officially recognises Control Bionics as a registered medical device manufacturer, enabling commercial sales and revenue generation throughout Great Britain – including England, Scotland, and Wales.
Early Trials Signal Market Readiness
With regulatory barriers cleared, Control Bionics is accelerating commercial execution through three active pilot programs demonstrating NeuroStrip’s clinical and performance capabilities. These trials involve heavyweight collaborators such as Dr Tom Maden-Wilkinson, a renowned sEMG expert affiliated with the University of Lancaster and University of Sheffield, as well as the University of Nottingham and British Olympics. Additional customer trials are slated to commence in September 2026, underscoring the company’s commitment to validating the device across rehabilitation, research, and elite sports sectors.
Strategic International Expansion
UK registration complements NeuroStrip’s existing US FDA approval, forming part of Control Bionics’ broader strategy to scale its neurotechnology platform across major international markets. CEO Jeremy Steele emphasised the UK’s significance, citing its well-funded rehabilitation and research infrastructure alongside elite sports markets as fertile ground for NeuroStrip’s applications. Feedback from these early adopters will shape the company’s UK market-entry approach and inform its expansion across Europe.
Technology and Market Positioning
NeuroStrip is classified under the Global Medical Device Nomenclature (GMDN) as a psychophysiological biofeedback system, reflecting its role in capturing and converting muscle electrical activity into actionable data. Control Bionics’ non-invasive neural-signal technology spans multiple applications beyond assistive communication, including performance enhancement, rehabilitation, and medical research. The UK market access milestone follows a series of regulatory wins and commercial partnerships, positioning the company to capitalise on growing demand for objective neural-signal solutions.
Bottom Line?
Control Bionics’ UK MHRA registration marks a crucial step from regulatory clearance to commercial rollout, with early trials poised to validate NeuroStrip’s value and inform European expansion.
Questions in the middle?
- How will feedback from UK pilot programs influence NeuroStrip’s commercial strategy?
- What timeline can investors expect for revenue generation from UK and European markets?
- Will Control Bionics pursue further regulatory approvals to accelerate global scale?